The meteoric rise of telehealth and other types of virtual care during the Covid-19 pandemic sparked some of the highest funding in digital health’s history. This avalanche of investment — akin to the boom in electronic health record systems more than a decade ago — created a media frenzy, with health care and consumer media outlets creating the impression that digital health will solve the industry’s problems.
Not all of this enthusiasm was misplaced. Digital health continues to massively change the health care industry. Yet health care providers, payers, and investors have become warier about funding and partnering with startups. Several high-profile and well-funded digital health companies were recently shown to have misled, overprescribed, or were outright fraudulent in their claims toward customers and partners.
In the wake of these scandals, the investment community needs to raise the bar and demand transparent and verifiable evidence of clinical claims and financial return on investment for digital health solutions.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.
Already have an account? Log in
Already have an account? Log in
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect